ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -482.83

ABL Bio Inc. Price to Earnings Ratio (P/E) is -482.83 on January 14, 2025, a -19.45% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

ABL Bio Inc. 52-week high Price to Earnings Ratio (P/E) is -350.75 on February 08, 2024, which is 27.36% above the current Price to Earnings Ratio (P/E).
ABL Bio Inc. 52-week low Price to Earnings Ratio (P/E) is -717.01 on October 14, 2024, which is -48.50% below the current Price to Earnings Ratio (P/E).
ABL Bio Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -474.84.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years